Am J Blood Res 2012;2(2):98-104
Review Article
A long road of T-cells to cure cancer: from adoptive immunotherapy with
unspecific cellular products to donor lymphocyte infusions and transfer of
engineered tumor-specific T-cells
Alexandros Spyridonidis, Maria Liga
Hematology Division, BMT Unit, University Hospital of Patras, 26500 Rio, Greece
Received March 25, 2012; accepted May 3, 2012; Epub May 18, 2012; Published June 15, 2012
Abstract: The notion that immunocompetent cells, contained within adult bone marrow or peripheral blood, are capable of
mediating an antitumor effect was first validated experimentally in 1957. T-cell immunotherapy for malignant disease is now
routinely used in the context of allogeneic bone marrow transplantation. After 50 years of investigations into the use of T-cells
for cancer therapy, adoptive cellular immunotherapy for cancer has progressed from the delivery of unspecific cellular
products to the transfer of engineered tumor-specific T-cells. Adoptive cellular immunotherapy for cancer has now reached a
stage of increasing feasibility and efficacy. (AJBR1203003).
Keywords: Immunocompetent cells, antitumor effect, T-cell immunotherapy, allogeneic bone marrow transplantation,
tumor-specific T-cells
Address all correspondence to:
Dr. Alexandros Spyridonidis
BMT Unit, Hematology Division
University Hospital of Patras, 26500 Rio
Patras, Greece.
E-mail: spyridonidis@upatras.gr
Review Article
A long road of T-cells to cure cancer: from adoptive immunotherapy with
unspecific cellular products to donor lymphocyte infusions and transfer of
engineered tumor-specific T-cells
Alexandros Spyridonidis, Maria Liga
Hematology Division, BMT Unit, University Hospital of Patras, 26500 Rio, Greece
Received March 25, 2012; accepted May 3, 2012; Epub May 18, 2012; Published June 15, 2012
Abstract: The notion that immunocompetent cells, contained within adult bone marrow or peripheral blood, are capable of
mediating an antitumor effect was first validated experimentally in 1957. T-cell immunotherapy for malignant disease is now
routinely used in the context of allogeneic bone marrow transplantation. After 50 years of investigations into the use of T-cells
for cancer therapy, adoptive cellular immunotherapy for cancer has progressed from the delivery of unspecific cellular
products to the transfer of engineered tumor-specific T-cells. Adoptive cellular immunotherapy for cancer has now reached a
stage of increasing feasibility and efficacy. (AJBR1203003).
Keywords: Immunocompetent cells, antitumor effect, T-cell immunotherapy, allogeneic bone marrow transplantation,
tumor-specific T-cells
Address all correspondence to:
Dr. Alexandros Spyridonidis
BMT Unit, Hematology Division
University Hospital of Patras, 26500 Rio
Patras, Greece.
E-mail: spyridonidis@upatras.gr
| AJBR Copyright © 2011-present, All rights reserved. Published by e-Century Publishing Corporation, Madison, WI 53711, USA |
 |  |  |  |  |  |  |